Heidi L. Wagner Sells 1,774 Shares of Alexion Pharmaceuticals, Inc. (ALXN) Stock

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) SVP Heidi L. Wagner sold 1,774 shares of the stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total value of $206,333.94. Following the completion of the sale, the senior vice president now owns 47,212 shares in the company, valued at approximately $5,491,227.72. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down $8.68 on Thursday, hitting $108.47. The stock had a trading volume of 3,723,831 shares, compared to its average volume of 2,054,928. The firm has a market cap of $25,400.00, a price-to-earnings ratio of 48.42, a P/E/G ratio of 0.96 and a beta of 1.16. Alexion Pharmaceuticals, Inc. has a 12 month low of $96.18 and a 12 month high of $149.34. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.21. The company had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. Alexion Pharmaceuticals’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.26 EPS. equities analysts anticipate that Alexion Pharmaceuticals, Inc. will post 4.82 EPS for the current year.

Several research analysts have weighed in on the company. Piper Jaffray Companies reiterated an “overweight” rating and set a $170.00 price objective on shares of Alexion Pharmaceuticals in a research report on Monday, October 23rd. Stifel Nicolaus lowered their price objective on Alexion Pharmaceuticals from $165.00 to $159.00 and set a “buy” rating on the stock in a research report on Tuesday, October 24th. Royal Bank of Canada increased their price objective on Alexion Pharmaceuticals to $166.00 in a research report on Tuesday, October 24th. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price objective on the stock in a research report on Tuesday, October 31st. Finally, TheStreet cut Alexion Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Friday, November 10th. One analyst has rated the stock with a sell rating, two have issued a hold rating and twenty have issued a buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $153.10.

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALXN. Jennison Associates LLC grew its holdings in shares of Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock worth $748,116,000 after purchasing an additional 4,682,336 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Alexion Pharmaceuticals by 4,509.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock worth $124,037,000 after purchasing an additional 864,967 shares in the last quarter. Alkeon Capital Management LLC acquired a new stake in shares of Alexion Pharmaceuticals during the 3rd quarter worth $70,145,000. Wells Fargo & Company MN grew its holdings in shares of Alexion Pharmaceuticals by 32.7% during the 3rd quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock worth $218,647,000 after purchasing an additional 383,713 shares in the last quarter. Finally, Pictet Asset Management Ltd. grew its holdings in shares of Alexion Pharmaceuticals by 46.7% during the 3rd quarter. Pictet Asset Management Ltd. now owns 1,126,275 shares of the biopharmaceutical company’s stock worth $158,005,000 after purchasing an additional 358,695 shares in the last quarter. 94.04% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Heidi L. Wagner Sells 1,774 Shares of Alexion Pharmaceuticals, Inc. (ALXN) Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/08/heidi-l-wagner-sells-1774-shares-of-alexion-pharmaceuticals-inc-alxn-stock.html.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply